| Project/Area Number |
15K11292
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
HARADA Koji 山口大学, 大学院医学系研究科, 助教 (60253217)
|
|---|
| Research Collaborator |
FERDOUS Tarannum
MINAMI Haruyasu
FUJIWARA Rieko
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | mTOR阻害剤 / ラパマイシン / ５-FU / 老化防止 / 健康寿命延長 / 口腔癌 / 口腔扁平上皮癌 / Rapamycin / 5-FU / 併用療法 / リンパ管新生抑制 / 細胞老化抑制 / mTOR阻害 / アポトーシス / 健康寿命 |
|---|
| Outline of Final Research Achievements |
We investigated the combined effect one of mTOR inhibitors (rapamycin, everolimus or temsirolimus) and any of conventional anticancer agents (5-FU, CDDP, DOC, PTX, C-mab or radiation). Rapamycin in combination with 5-FU exerted maximum growth inhibitory effects on OSCC cell lines and nude mice tumors. Immunohistochemical staining showed that the expressions of p16, VEGF and podoplanin were down-regulated, and the expressions of PI3K, Akt , p27, and p21 were up-regulated on nude mice tumors treated with rapamycin and 5-FU.
These findings suggested that the combined therapy of rapamycin and 5-FU might be an new oral cancer treatments focused on mTOR inhibition leading to the anti-aging prevention and the healthy life-span extension.
|
